NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the initiation
